News Rob Bent News Rob Bent

7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma Receives $4.7MM Gra​nt to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.

Read More
News Rob Bent News Rob Bent

New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors

7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19, and Influenza Vaccines

7 Hills Pharma announces the successful completion of a Phase I clinical trial for 7HP349, an oral immunostimulant that enhances immuno-oncology drugs, COVID-19, and influenza vaccines. The study demonstrated excellent safety, tolerability, and pharmacokinetics, paving the way for Phase II clinical trials in solid tumors and vaccination for immunocompromised populations.

Read More
News Rob Bent News Rob Bent

Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research

Researchers from the Texas Heart Institute, UTMB, and 7 Hills Pharma have pioneered a groundbreaking study on the use of 7HP349, an oral integrin activator, as a vaccine adjuvant. This research, published in Nature Partner Journal Vaccines, shows how 7HP349 enhances immune responses, with promising applications for Chagas disease and COVID-19 vaccines, particularly in immunocompromised individuals.

Read More
News Rob Bent News Rob Bent

IMMUNE ACTIVATORS – Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

Read More